Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC raised its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 6.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 662,594 shares of the company's stock after purchasing an additional 38,490 shares during the quarter. Geode Capital Management LLC owned 1.26% of Janux Therapeutics worth $30,107,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in JANX. Janus Henderson Group PLC increased its position in shares of Janux Therapeutics by 40.0% during the 3rd quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company's stock valued at $114,587,000 after purchasing an additional 721,563 shares during the last quarter. Logos Global Management LP lifted its stake in Janux Therapeutics by 400.0% in the second quarter. Logos Global Management LP now owns 750,000 shares of the company's stock worth $31,418,000 after purchasing an additional 600,000 shares during the last quarter. Point72 Asset Management L.P. boosted its position in shares of Janux Therapeutics by 190.2% during the third quarter. Point72 Asset Management L.P. now owns 395,875 shares of the company's stock valued at $17,985,000 after buying an additional 259,445 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Janux Therapeutics by 202.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company's stock worth $10,639,000 after buying an additional 156,675 shares during the period. Finally, Barclays PLC lifted its stake in shares of Janux Therapeutics by 496.5% during the 3rd quarter. Barclays PLC now owns 174,061 shares of the company's stock worth $7,907,000 after acquiring an additional 144,883 shares during the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Stock Down 1.9 %

Shares of JANX traded down $1.07 during mid-day trading on Friday, reaching $54.10. The company had a trading volume of 492,668 shares, compared to its average volume of 1,551,955. Janux Therapeutics, Inc. has a 52-week low of $7.79 and a 52-week high of $71.71. The stock has a 50 day moving average of $54.43 and a two-hundred day moving average of $47.43.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.18). The firm had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm's revenue for the quarter was down 82.6% on a year-over-year basis. On average, sell-side analysts predict that Janux Therapeutics, Inc. will post -1.35 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. William Blair reaffirmed an "outperform" rating on shares of Janux Therapeutics in a research report on Tuesday, December 3rd. BTIG Research raised their target price on shares of Janux Therapeutics from $82.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday, December 3rd. Scotiabank lifted their price target on shares of Janux Therapeutics from $42.00 to $62.00 and gave the company a "sector perform" rating in a research note on Wednesday, December 4th. Leerink Partnrs raised Janux Therapeutics to a "strong-buy" rating in a research note on Friday, November 22nd. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $200.00 target price on shares of Janux Therapeutics in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $89.90.

Insider Buying and Selling

In related news, CEO David Alan Campbell sold 25,000 shares of the business's stock in a transaction that occurred on Tuesday, December 24th. The stock was sold at an average price of $56.19, for a total transaction of $1,404,750.00. Following the completion of the sale, the chief executive officer now directly owns 217,054 shares in the company, valued at approximately $12,196,264.26. The trade was a 10.33 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Ventures Xi L.P. Avalon sold 1,843 shares of the firm's stock in a transaction on Thursday, October 17th. The shares were sold at an average price of $50.02, for a total value of $92,186.86. Following the completion of the transaction, the insider now owns 6,371 shares in the company, valued at $318,677.42. The trade was a 22.44 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 92,801 shares of company stock valued at $5,174,735. 29.40% of the stock is owned by company insiders.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.